FDA Approves 35 Novel Medicines in Fiscal Year 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Approves 35 Novel Medicines in Fiscal Year 2011


ePT--the Electronic Newsletter of Pharmaceutical Technology

At a press conference held Nov. 10, 2011, FDA Commissioner Margaret Hamburg said the agency had approved 35 novel medicines in fiscal year 2011. Among the approved products were two drugs for late-stage metastatic melanoma and the first drug to treat Hodgkins lymphoma in 30 years. Other approvals included drugs to treat late-stage prostate cancer, thyroid cancer, metastatic breast cancer, and late-stage lung cancer.

Hamburg highlighted the agency’s efforts to bring new drugs to market quickly and efficiently while maintaining high standards for drug safety and effectiveness. “FDA approved nearly 70% of these 35 new drugs before any other regulatory agency in the world,” she said. Of the 23 cancer drugs approved between 2003 and 2010 by FDA and the European Medicines Agency, all 23 were approved first in the US, said Hamburg, citing a study published in Health Affairs.

FDA has expanded its drug-approval pathways to include Fast Track, Accelerated Approval, Priority Review, and Expanded Access programs, which are designed to speed the testing, availability, and approval of drugs in various ways. Almost half of the 35 new drugs approved in fiscal year 2011 were approved under priority review, said Hamburg. Under this program, FDA aims to complete its review of safety and effectiveness in six months.

The agency also has shown flexibility regarding clinical trials. Clinical requirements for many of the newly approved drugs were streamlined to permit smaller, shorter, or fewer studies than previous studies. FDA approved several drugs on the basis of single-arm studies or studies with extremely small patient populations, Hamburg said.

FDA’s efforts to modernize its regulatory pathways depend on its initiatives to strengthen regulatory science, said Hamburg. The agency’s Advancing Regulatory Science Initiative currently seeks to identify opportunities to invest in regulatory science. Last year, FDA and the National Institutes of Health launched a Regulatory Science Initiative to encourage research in this field. The agency also established several Centers of Excellence in Regulatory Science, including sites at Georgetown University and at the University of Maryland.

See related Pharm Tech articles:

Accelerated Approvals Could Raise Risks for Patients (blog post)

FDA Establishes Two Centers for Regulatory Science (ePT)

FDA Outlines Strategy to Spur Biomedical Innovation (ePT)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here